CURESPONSE

Curesponse's technology represents the next step in personalized cancer medicine, advancing prediction capabilities beyond genomics to understand how cancer treatments will affect the patient's tumor cells when they are in their native tumor... As the availability of novel cancer drugs, and the biomarkers that help oncology teams select them, is constantly breaking new ground, the challenge of identifying which treatment will be most effective is growing... Curesponse has developed a 3-dimensional tissue culture system for modeling cancer growth and drug response. The platform, preserves the cancer tissue architecture (including vasculature and immune system) accurately reflecting the cancer growth found in the body

Also known as: Curesponse Israel, CURESPONSE LTD, Curesponse UK

Registration numbers: FC038171 (CH)

Primary location: Cotswold United Kingdom